137 related articles for article (PubMed ID: 37897456)
21. Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis.
Cahn A; Melzer-Cohen C; Pollack R; Chodick G; Shalev V
Diabetes Obes Metab; 2019 Feb; 21(2):340-348. PubMed ID: 30207040
[TBL] [Abstract][Full Text] [Related]
22. Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases.
Komuro I; Kadowaki T; Bodegård J; Thuresson M; Okami S; Yajima T
Diabetes Obes Metab; 2021 Apr; 23 Suppl 2():19-27. PubMed ID: 33835641
[TBL] [Abstract][Full Text] [Related]
23. Sodium-Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Population-Based Investigation.
Kwon O; Myong JP; Lee Y; Choi YJ; Yi JE; Seo SM; Jang SW; Kim PJ; Lee JM
J Am Heart Assoc; 2023 Jul; 12(14):e027824. PubMed ID: 37421263
[TBL] [Abstract][Full Text] [Related]
24. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis.
Usman MS; Siddiqi TJ; Memon MM; Khan MS; Rawasia WF; Talha Ayub M; Sreenivasan J; Golzar Y
Eur J Prev Cardiol; 2018 Mar; 25(5):495-502. PubMed ID: 29372664
[TBL] [Abstract][Full Text] [Related]
25. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
Lytvyn Y; Bjornstad P; Udell JA; Lovshin JA; Cherney DZI
Circulation; 2017 Oct; 136(17):1643-1658. PubMed ID: 29061576
[TBL] [Abstract][Full Text] [Related]
26. Sodium-glucose cotransporter 2 inhibitors and cardiovascular clinical outcomes in acute heart failure: A narrative review.
Rodriguez R; Kaluzna SD
Am J Health Syst Pharm; 2023 Jun; 80(13):818-826. PubMed ID: 36971375
[TBL] [Abstract][Full Text] [Related]
27. Impact of SGLT2 Inhibitors on AF Recurrence After Catheter Ablation in Patients With Type 2 Diabetes.
Abu-Qaoud MR; Kumar A; Tarun T; Abraham S; Ahmad J; Khadke S; Husami R; Kulbak G; Sahoo S; Januzzi JL; Neilan TG; Baron SJ; Martin D; Nohria A; Reynolds MR; Kosiborod M; Dani SS; Ganatra S
JACC Clin Electrophysiol; 2023 Oct; 9(10):2109-2118. PubMed ID: 37565953
[TBL] [Abstract][Full Text] [Related]
28. Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs.
Hussain A; Ramsey D; Lee M; Mahtta D; Khan MS; Nambi V; Ballantyne CM; Petersen LA; Walker AD; Kayani WT; Butler J; Slipczuk L; Rogers JG; Bozkurt B; Navaneethan SD; Virani SS
JACC Heart Fail; 2023 Aug; 11(8 Pt 1):933-942. PubMed ID: 37204363
[TBL] [Abstract][Full Text] [Related]
29. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.
Dong YH; Chang CH; Lin JW; Yang WS; Wu LC; Toh S
Diabetes Obes Metab; 2022 Aug; 24(8):1623-1637. PubMed ID: 35491533
[TBL] [Abstract][Full Text] [Related]
30. Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines.
Gongora CA; Drobni ZD; Quinaglia Araujo Costa Silva T; Zafar A; Gong J; Zlotoff DA; Gilman HK; Hartmann SE; Sama S; Nikolaidou S; Suero-Abreu GA; Jacobsen E; Abramson JS; Hochberg E; Barnes J; Armand P; Thavendiranathan P; Nohria A; Neilan TG
JACC Heart Fail; 2022 Aug; 10(8):559-567. PubMed ID: 35902159
[TBL] [Abstract][Full Text] [Related]
31. Uptake of SGLT2i and Outcomes in Patients with Diabetes and Heart Failure: A Population-Based Cohort and a Specialized Clinic Cohort.
Gagnon LR; Hazra D; Perera K; Wang K; Kashyap N; Sadasivan C; Youngson E; Chu L; Dover DC; Kaul P; Simpson S; Bello A; McAlister FA; Oudit GY
Am Heart J; 2024 Aug; 274():11-22. PubMed ID: 38670300
[TBL] [Abstract][Full Text] [Related]
32. Role of sodium glucose co-transporter 2 inhibitors in patients with heart failure: an elusive mechanism.
Imran H; Nester W; Elgendy IY; Saad M
Ann Med; 2020 Aug; 52(5):178-190. PubMed ID: 32393068
[TBL] [Abstract][Full Text] [Related]
33. Long-Term Mortality and SGLT2 Inhibitors in Type 2 Diabetes with and without Renal Impairment: An Observational Cohort Study.
Al-Muhaiteeb A; Alahmad B; Abu-Farha M; Abubaker J; Thanaraj TA; Ali H; Al-Mulla F; Qaddoumi M
Med Princ Pract; 2024; 33(3):251-259. PubMed ID: 38359814
[TBL] [Abstract][Full Text] [Related]
34. Importance of sodium-glucose cotransporter 2 inhibitor use in diabetic patients with acute heart failure.
Kambara T; Shibata R; Osanai H; Nakashima Y; Asano H; Murohara T; Ajioka M
Ther Adv Cardiovasc Dis; 2019; 13():1753944719894509. PubMed ID: 31854243
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Sodium-Glucose Cotransporter 2 Inhibitors vs Glucagonlike Peptide-1 Receptor Agonists and Incidence of Dry Eye Disease in Patients With Type 2 Diabetes in Taiwan.
Su YC; Hung JH; Chang KC; Sun CC; Huang YH; Lee CN; Hung MJ; Lai CC; Shao SC; Lai EC
JAMA Netw Open; 2022 Sep; 5(9):e2232584. PubMed ID: 36136333
[TBL] [Abstract][Full Text] [Related]
36. Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus.
Suzuki Y; Kaneko H; Okada A; Itoh H; Matsuoka S; Fujiu K; Michihata N; Jo T; Takeda N; Morita H; Kamiya K; Matsunaga A; Ako J; Node K; Yasunaga H; Komuro I
Cardiovasc Diabetol; 2022 May; 21(1):67. PubMed ID: 35585590
[TBL] [Abstract][Full Text] [Related]
37. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
McGuire DK; Shih WJ; Cosentino F; Charbonnel B; Cherney DZI; Dagogo-Jack S; Pratley R; Greenberg M; Wang S; Huyck S; Gantz I; Terra SG; Masiukiewicz U; Cannon CP
JAMA Cardiol; 2021 Feb; 6(2):148-158. PubMed ID: 33031522
[TBL] [Abstract][Full Text] [Related]
38. Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
Kim YG; Jeon JY; Han SJ; Kim DJ; Lee KW; Kim HJ
Diabetes Obes Metab; 2018 Aug; 20(8):1852-1858. PubMed ID: 29569427
[TBL] [Abstract][Full Text] [Related]
39. Chapter 3: Clinical Trials of Sodium-Glucose Co-Transporter-2 Inhibitors for Treatment of Heart Failure.
Greene SJ; Butler J; Kosiborod MN
Am J Med; 2024 Feb; 137(2S):S25-S34. PubMed ID: 38184323
[TBL] [Abstract][Full Text] [Related]
40. The comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A Scandinavian cohort study.
Ueda P; Wintzell V; Dahlqwist E; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Melbye M; Hviid A; Svanström H; Pasternak B
Diabetes Obes Metab; 2022 Mar; 24(3):473-485. PubMed ID: 34738703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]